National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Omacor® (a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic acid (EPA) ethyl ester and 38% docosahexaenoic acid (DHA) ethyl ester) is indicated as an adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy.  Omacor® is also indicated for the treatment of endogenous hypertriglyceridaemia as a supplement to diet, when dietary measures alone are insufficient to produce an adequate response.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
11/02/2013  19/04/2013 Reimbursement Not Recommended

The NCPE believe that Omacor® is not a cost-effective adjuvant treatment for patients post-myocardial infarction in the Irish Healthcare Setting.  The cost effectiveness of Omacor® for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated.

Omacor Summary